← 返回

FOXM1 在肿瘤免疫学中的作用:对癌症治疗策略的启示

英文原题:The role of FOXM1 in tumor immunology: implications for cancer treatment strategies.

查看英文原题

The role of FOXM1 in tumor immunology: implications for cancer treatment strategies.

PubMed 2026/07/06(内容时间) Hum Cell Q3 · IF 2.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

叉头框蛋白M1(FOXM1)是叉头框转录因子家族的重要成员,在多种人类恶性肿瘤中显著过表达,并通过调控癌细胞增殖和侵袭推动肿瘤进展,因此是有吸引力的抗癌治疗靶点。然而,关于FOXM1调控肿瘤免疫作用的全面综述仍然缺乏。本综述总结FOXM1调节肿瘤免疫的多重作用,并评估其作为治疗靶点的潜力。FOXM1可通过调节免疫检查点、影响巨噬细胞极化,以及改变T细胞分化和浸润,深刻调节肿瘤免疫微环境。此外,FOXM1还调控多种关键免疫信号通路,包括信号转导及转录激活因子1(STAT1)和干扰素刺激基因(STING)通路。本文还讨论靶向FOXM1提高免疫治疗疗效的潜力,特别关注克服免疫逃逸、神经毒性和治疗耐药相关挑战。本综述同时总结FOXM1靶向药物开发和应用的现状,包括小分子抑制剂、肽类疗法和联合治疗策略,凸显FOXM1作为癌症治疗新型多功能靶点的临床前景。

展开英文摘要原文

Forkhead box protein M1 (FOXM1) is a pivotal member of the forkhead box family of transcription factors, characterized by its marked overexpression in a wide range of human malignancies and its critical role in driving tumor progression through the regulation of cancer cell proliferation and invasion, making it an attractive target for anti-cancer therapy.

However, comprehensive reviews detailing the role of FOXM1 in regulating tumor immunity are still lacking. In this review, we summarize the multiple roles of FOXM1 in regulating tumor immunity and assess its potential as a therapeutic target. FOXM1 plays a crucial role in regulating the tumor immune microenvironment by modulating immune checkpoints, influencing macrophage polarization, and affecting T cell differentiation and infiltration.

Furthermore, FOXM1 also plays a regulatory role in key immune-related signaling pathways, including signal transducer and activator of transcription 1 (STAT1) and interferon stimulated gene (STING).

Furthermore, the potential of targeting FOXM1 to enhance the efficacy of immunotherapies is discussed, with particular emphasis on overcoming challenges related to immune evasion, neurotoxicity, and therapeutic resistance. This review also summarizes the current landscape of FOXM1-targeted drug development and application, including small molecule inhibitors, peptide-based therapeutics, and combination treatment strategies, highlighting the promising clinical prospects of FOXM1 as a novel and multifaceted target in cancer therapy.

论文信息

作者
Wang S、Zhang K、Yong T、An Y、Bai S、Yuan C、Liu H、Liu T
单位
Key Laboratory of Preclinical Study for New Drugs of Gansu Province, Institute of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Lanzhou University, Lanzhou, 730000, People's Republic of China. wangsp16@126.com.China
文献类型
综述
期刊
Human cell2026 Jul 6
原文标识
PubMed 42406290 · DOI 10.1007/s13577-026-01407-y